Keryx Biopharma (KERX) Misses Q3 EPS by 19c

November 9, 2016 7:03 AM EST
Get Alerts KERX Hot Sheet
Trade KERX Now!
Join SI Premium – FREE

Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.

Keryx Biopharma (NASDAQ: KERX) reported Q3 EPS of ($0.39), $0.19 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $6.3 million versus the consensus estimate of $5.37 million.

At September 30, 2016, the company had cash and cash equivalents of $132.2 million.

For earnings history and earnings-related data on Keryx Biopharma (KERX) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Earnings

Related Entities

Earnings

Add Your Comment